Affinity DataKi: 6nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 7nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 11nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 15nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 15nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 16nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 17nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 20nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 23nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 38nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 43nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 43nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 50nMAssay Description:Inhibition of purified human SphK1 assessed as inhibition of formation of [33P]-S1P after 50 mins by scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 52nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 63nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 73nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 81nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 93nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 94nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 150nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 150nMAssay Description:Displacement of radiolabeled GW2331 from human PPAR alpha by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 160nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 200nMAssay Description:Inhibition of purified human SphK1 assessed as inhibition of formation of [33P]-S1P after 50 mins by scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 210nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 240nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 270nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 300nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 334nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 340nMAssay Description:Displacement of radiolabeled GW2331 from human PPAR alpha by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 348nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 360nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 394nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 440nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 440nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 500nMAssay Description:Inhibition of purified human SphK1 assessed as inhibition of formation of [33P]-S1P after 50 mins by scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 500nMAssay Description:Inhibition of purified human SphK2 assessed as inhibition of formation of [33P]-S1P after 50 mins by scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 560nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 810nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 840nMAssay Description:Displacement of radiolabeled GW2331 from human PPAR alpha by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 840nMAssay Description:Displacement of radiolabeled GW2331 from human PPAR alpha by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 1.10E+3nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 1.10E+3nMAssay Description:Displacement of radiolabeled GW2331 from human PPAR alpha by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 1.10E+3nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 1.10E+3nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 1.20E+3nMAssay Description:Displacement of radiolabeled GW2331 from human PPAR alpha by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 1.40E+3nMAssay Description:Inhibition of purified human SphK1 assessed as inhibition of formation of [33P]-S1P after 50 mins by scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 1.60E+3nMAssay Description:Displacement of radiolabeled GW2331 from human PPAR alpha by SPA assayMore data for this Ligand-Target Pair
Affinity DataKi: 1.60E+3nMAssay Description:Displacement of radiolabeled darglitazone from human PPAR gamma by SPA assayMore data for this Ligand-Target Pair